Posts by Raymond J. March
Raymond J. March is a Research Fellow at the Independent Institute and Assistant Professor of Agribusiness and Applied Economics at North Dakota State University.
More Executive Orders Will Not Fix Healthcare


Draconian measures to “flatten the curve” were implemented to prevent the healthcare sector from becoming overwhelmed with infected patients. Now, as many states reopen for business, it seems relatively few healthcare facilities are overwhelmed. However, much of the healthcare industry is still struggling. Becker Hospital Review finds that more than 250 hospitals are furloughing […]

Private Enterprise Continues to Flatten the Curve


A few weeks ago, I published an op-ed in The Hill entitled “Trust Private Enterprise to Flatten the Curve.” There I argued that markets, rather than the heavy hand of government, are our best hope to combat COVID-19. Between then and now, markets have continued to provide patients and healthcare professionals with urgently needed […]

Economic Prosperity or Pandemic Protection: Why Not Both?


United States government officials previously estimated the COVID-19 virus would infect between 70 million and 150 million Americans, causing between 100,000 and 240,000 fatalities. Both estimates made the coronavirus the most devastating pandemic since the Spanish Flu (which some consider the deadliest pandemic ever). But after re-examining the data, these estimates have been dramatically […]

Cut Regulations and Get COVID-19 Drugs to Patients


As the coronavirus pandemic continues to ravage the U.S. healthcare system, many healthcare professionals are struggling to find enough medical supplies to treat patients and to avoid becoming infected themselves. A recent New York Post article finds nurses working in a New York City hospital resorted to covering themselves with garbage bags because the […]

Right-to-Try Laws Can Help Drugmakers Combat the Coronavirus


President Trump recently announced he is extending social distancing guidelines to April 30th. He initially hoped to lift them by Easter. This is far from the first time he has changed his mind on how to best handle the coronavirus pandemic. Although frustrating, the President’s indecisiveness is understandable. The United States recently surpassed China […]

To Battle Covid-19, Cut Regulation!


Nearly three weeks ago, the United States reported 230 confirmed cases of the Covid-19 virus and a dozen fatalities. On March 24, the United States reached 64,645 confirmed cases and 908 deaths. In New York City the death toll hit 192. As anyone with a TV or digital news feed knows, the virus is […]

Favor Local Action to Combat the Coronavirus


Three months ago, the novel coronavirus first appeared in Wuhan, China. Now, it is considered a global pandemic. As of March 18th, the virus has infected over 169,000 individuals, resulting in 8,732 deaths—and counting. The United States as of this writing has approximately 7,769 confirmed cases of the coronavirus and at least 125 related […]

FDA Acknowledges Coronavirus Is Causing More Drug Shortages


The first outbreak of the coronavirus occurred in China nearly two months ago. The disease quickly spread through the country. As of March 5th, the coronavirus is responsible for over 80,000 confirmed cases and nearly 3,400 deaths across China. Globally over 98,000 people are infected, resulting in nearly 4,000 deaths. At this time, the […]

FDA’s Approval of Generic Daraprim Offers Lessons on Drugs Prices


In 2015, Turning Pharmaceuticals CEO Martin Shkreli increased the price of the drug Daraprim nearly 5,000 percent from $13.50 to $750 per pill. The price hike generated widespread outrage, earning Shkreli the moniker “Pharma Boy” and the designation, “pharmaceutical greed villain.” Daraprim became “the poster child for the issue of high drug prices.”

Who Should Regulate Tobacco Products? Less Is More!


Over the past year, the Food and Drug Administration undertook a “historic crackdown” of the e-cigarette industry. Recent bans on selected e-cigarette flavors are certainly a step in this direction. With promises for “aggressive action” by FDA Commissioner Stephen Hahn, more heavy-handed regulations are likely to follow. The FDA certainly has increased its regulatory […]

  • Catalyst
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org